Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 9/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.34 |
| ▸ | EP300 | Q09472 | 4/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | BCR | P11274 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31377434 | 0.83 | ABHD6 (0.40) | ABHD6DAGLAS1PR1ABL1BCR | |
| SCHEMBL31377380 | 0.79 | CYP2D6 (0.50) | S1PR1EP300 | |
| SCHEMBL31377215 | 0.77 | CYP2D6 (0.34) | ABHD6DAGLAABL1BCR | |
| SCHEMBL31377351 | 0.76 | NR1H2 (0.40) | — | |
| SCHEMBL31377105 | 0.75 | CYP2D6 (0.38) | — | |
| SCHEMBL31377217 | 0.74 | RORC (0.38) | — | |
| SCHEMBL31377193 | 0.74 | VEGFA (0.38) | — | |
| SCHEMBL31377211 | 0.74 | NR1H2 (0.45) | HDAC1 | |
| SCHEMBL31377178 | 0.74 | NR1H2 (0.45) | HDAC1 | |
| SCHEMBL31377297 | 0.73 | SMN1; SMN2 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091989-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | ABHD6 2017/4885DAGLA 3713/4885S1PR1 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.